Tools
RESEARCH — THE FILING TAPE #210

One of 147: OrbiMed Is the Only Tracked Holder of Spruce Biosciences — After a Delisting, a 1:75 Split, and a Nasdaq Return

Denominator: the 147 funds with Q2 13F data.
November 10, 2026

GetCoattail Research — a filings audit of Spruce Biosciences, Inc. (SPRB) through six filing lenses, as of the latest filings. Past patterns are not a promise of future results. For education only — not investment advice.

The Hype

Spruce Biosciences, Inc. (SPRB) is the issuer behind this audit — CIK 1683553, CUSIP 85209E208 (current) and 85209E109 (old, pre-split), listed on the Nasdaq Capital Market. Its recent history runs: Nasdaq delisting on April 29, 2025 for minimum bid price non-compliance, OTC trading from that date, a one-for-seventy-five (1:75) reverse stock split effective August 4, 2025, OTCQB trading under SPRBD from August 7, 2025, and a Nasdaq Capital Market return under SPRB on September 15, 2025. Every price window cited here falls after that return and split, so the windows are comparable; nothing earlier is cited.

Collaboration revenue fell from $10,089,000 (FY2023) to $4,911,000 (FY2024) to $0 (FY2025) — the Kaken License Agreement price was fully recognized by December 31, 2024 — while net losses ran $(47,919,000), $(53,036,000), and $(38,966,000). Total assets were $45,209,000 in FY2024 and $53,021,000 in FY2025. Shares outstanding were 1,372,043 at December 31, 2025 and 563,042 at December 31, 2024, split-restated; the pre-split count of 42,231,285 on April 11, 2025 divided by 75 gives 563,084, within 0.01% of the restated figure, a rounding difference. Both 10-Ks disclose going-concern doubt. No current market capitalisation is stated — the 10-K's June 30, 2025 nonaffiliate value of about $2.8 million at the OTCQB $5.44 close is historical, not current — and no per-share math is built on undated share counts.

On the citable post-return regime, the price is down sharply over a year but flat over two months. SPRB closed at $46.55 on November 6, 2026 — up 2.22% over 21 trading days (from $45.54 on October 8), up 0.76% over 63 (from $46.20 on August 10), down 13.80% since June 30 ($54.00), down 28.77% since March 31 ($65.35), down 46.56% since the 2025 year-end close ($87.11), and down 60.98% from a year ago ($119.29 on November 6, 2025, corroborated by the S-3's $124.51 on October 28, 2025). The short windows turned positive on a single day: November 6 rose 8.99% from $42.71 the day before. The cache holds 501 trading days, from November 7, 2024 to November 6, 2026, spanning the split and transition, so it is labeled here only as all available cache history — never as a full-year window — and no all-cache high, low, or first close is cited.

The question: what did the filings record while the price fell 61.0% from a year ago — a tracked holder through the delisting and split, broad-base direction, insider activity, the register's true count, the short ledger? Congress contributes no finding: the panel reports its data as unavailable, and that is not a zero.

The Tape

LensAs ofWhat the filings showDirection vs prior period
Superinvestors (13F)Jun 30, 20261 of 147 tracked managers holds; 200,000 shares ($10,800,000). OrbiMed Advisors, NEW.NEW; exits 0; options 0
All institutions (13F)Jun 30, 202663 holders (63 long) hold 2,002,949 shares ($108,161,532).Holders 31 → 63 (+32); value +130.6%; shares-vs-prior unavailable
Insiders (Form 4)Nov 7, 20260 buys / 0 sells in 90 days; 0 filings, no P/S transactions in window.1-year window now empty — the Parkman double-report aged out (Oct 6, 2025)
CongressOct 3, 2026Panel: data unavailable in window; staging 0 rows.No congress total is stated — unavailability is not a verified zero
13D/GAug 14, 2026Current-CUSIP aggregate: 26 filings (2 13D, 24 13G), 47 reporters, max 21.6%.As-filed row sum 6,284,213 shares (not shares held); issuer-wide scan adds 4 old-CUSIP filings
Short interestOct 15, 2026522,120 shares short, 6.62 days to cover; fails-to-deliver unavailable, not zero.Short up 45.28% from Jun 30; new peak above the Aug 31 count of 440,243
SPRB closes on the citable post-return regime: $119.29 one year ago, $87.11 at the 2025 year-end, $65.35 at March 31, $54.00 at June 30, $46.20 63 trading days ago, $45.54 21 trading days ago, $46.55 on November 6, 2026
Chart 1: SPRB closes, post-September 15, 2025 Nasdaq return regime only. 13F as of June 30, 2026 (45-day filing lag); Form 4 detail re-checked through November 7, 2026; Congress panel as of October 3, 2026 (data unavailable for SPRB); 13D/G latest filing August 14, 2026; short interest at the October 15, 2026 settlement.

Superinvestors. One of 147 tracked managers holds SPRB — a new name. OrbiMed Advisors filed August 14, 2026 with 200,000 shares, $10,800,000, 0.20% of its portfolio, change NEW. No SPRB option or exited rows exist. Two cross-checks lock the figure: 200,000 shares at the June 30 close of $54.00 equals $10,800,000 exactly, and OrbiMed's Schedule 13G filed the same day reports OrbiMed Advisors LLC with 132,200 shares (4.8%) plus OrbiMed Capital LLC with 67,800 shares (2.5%) — 200,000 shares, matching the 13F holding exactly. Counting note: the denominator is 147 funds with usable Q2 data, not the 149-fund roster. The tracked stake is about 10.0% of all institutions' reported shares (200,000 of 2,002,949), a same-quarter, same-price comparison.

All institutions. The broad base roughly doubled in count and more than doubled in value in Q2. Holders rose from 31 to 63 (all 63 long), reported shares reached 2,002,949, and reported value rose 130.6% (from $46,906,784 to $108,161,532). One change is not stated: shares versus the prior quarter is not in the source row (no prior-share, entered, or exited fields), so it is unavailable, not derived. Coverage note: the by-ticker file lacks SPRB; this lens uses the by-CUSIP file — a coverage fact, not a zero.

Insiders. The 90-day tape is empty, and now so is the 1-year tape. In the 90 days to November 7, 2026, there are 0 open-market buys and 0 open-market sells — 0 shares, $0 — across 0 filings: no Form 4 has been filed since July 29, 2026. The site panel's “Data unavailable — no Form 4 transactions for this ticker were parsed in the 90 days to Nov 7, 2026” and the missing site aggregate entry are consistent with this. The 1-year window to November 7, 2026 is also empty. The Parkman Healthcare Partners LLC cluster that the October 2 aggregate showed (2 buys, 512 shares, $9,170.33, against 4 sells, 514 shares, $9,840.23, all dated October 6, 2025) has aged out of the window: those transactions were one economic buy (256 shares) plus two economic sells (232 and 25 shares) reported twice across two filings, not 6 distinct transactions — aged-out history, not dropped silently. One flag is stated without its numbers: the aged-out filing prices sit far from the adjacent market-price regime for undetermined reasons, so no 1-year transaction price is cited here as a market price.

Congress. This lens contributes no finding. The site panel as of October 3, 2026 reads: “Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window.” The October 27 staging file holds zero SPRB rows, and the trades file is header-only by design; re-checked November 7, 2026, including the 52-document House PTR refresh: still none. Absence of parsed rows is not a verified zero, so no congress total is stated; any congress claim needs a direct PTR search first.

13D/G. The current-CUSIP aggregate counts 26 filings under CUSIP 85209E208: 2 Schedule 13D and 24 Schedule 13G, 13 amendments, 47 reporters, maximum 21.6%, latest filing August 14, 2026. Its as-filed reporter-row sum is 6,284,213 shares — rows, never shares held. An issuer-wide parsed-corpus scan finds more: 30 filings, 115 reporter rows, 16,879,590 shares, 70 reporter names, 37 reporter CIKs, same latest date and maximum. The entire gap is 4 filings under the old pre-split CUSIP 85209E109 (23 rows, 10,595,377 shares, 23 names): one RiverVest 13D/A dated January 10, 2025 carrying all 10,595,377 pre-split shares across 12 rows, plus three 0-share filings (Rosalind 13G/A, February 13, 2025; Rock Springs 13G/A and Radoff 13G/A, both August 13, 2025). The current-CUSIP subset reproduces the aggregate exactly (26 filings, 92 rows, 6,284,213 shares, 47 names), so the aggregate is the current-CUSIP count and the scan figures are parsed-corpus scan figures only. Joint filing dominates either way: as-filed sums double-count groups reporting the same shares — Carlyle's 13D/A of February 18, 2026 reports 50,893 shares across 10 reporters, and Ikarian's 121,356 shares read 21.6% (October 8, 2025), 11.4% (November 7, 2025), and 4.8% (May 7, 2026) as outstanding grew — percents as filed at different dates, not comparable. The latest filings, all August 14, 2026, are OrbiMed's 13G (132,200 + 67,800 = 200,000, matching the 13F holding), AWM's 13G (146,988 shares, 5.1%), ADAR1's 13G/A (67,717 shares, 2.5%), and a Citadel 13G/A (maximum 21.6%: Ikarian, October 8, 2025). A separate older corpus (2021–2024) holds 36 rows, all Spruce Biosciences, Inc. (16 Schedule 13G/A, 12 Schedule 13D/A, 8 Schedule 13G), under the old CUSIP (27 rows) or a blank CUSIP (9 rows); no predecessor split is needed, and the old CUSIP is the pre-split common CUSIP.

Short interest. The bear trade grew through the summer, eased from its August peak, then jumped to a new high in October; the failure lens is missing, not clean. FINRA short interest: 522,120 shares at October 15, 2026, 6.62 days to cover. Series: 359,389 (June 30), 415,860 (July 15), 429,122 (July 31), 403,031 (August 14), 440,243 (August 31), 416,140 (September 15), 431,541 (September 30), 522,120 (October 15, the peak) — up 45.28% from June 30 and 18.60% above the August 31 peak. The October 30 settlement file publishes November 10, 2026 under the FINRA schedule, so it was not available at writing time. Fails-to-deliver are unavailable for SPRB: the ticker has no rows in the SEC fails panel and no entry in the site's fails extract, and absence from a threshold-based fails list is not a verified zero — so no fails figure is cited here at all. Short interest as a share of outstanding is not computed: no dated outstanding count for October 15, 2026 exists here.

SPRB short interest: 8 FINRA settlements, June 30 to October 15, 2026, latest 522,120 shares, a new peak above the August 31 count of 440,243; fails-to-deliver unavailable, not zero
Chart 2: SPRB short interest, 8 FINRA settlements from June 30 to October 15, 2026. Latest settlement October 15, 2026: 522,120 shares, 6.62 days to cover. Fails-to-deliver are unavailable for SPRB and no fails figure is cited.

The Gap

The tension here is one new holder against a shrinking company. OrbiMed — the only tracked fund holding SPRB — opened its position in Q2, when the broad base doubled in count and value rose 130.6%, while revenue went to $0 and both 10-Ks flagged going-concern doubt. The Q2 snapshot ends June 30 (close $54.00); the price stood at $46.55 on November 6, after a single-day 8.99% rise — the short windows are positive only because of that day. Nothing in the Q2 filings says what OrbiMed or the broad base did during the July–November leg down; the Q3 filings, due by November 16, 2026, first check whether the new position was held, added, or exited. Reading Q2 accumulation as a call on the October price would mistake a lagging picture for a live one.

Concentration cuts a different way here than in a multi-holder audit: with one tracked holder, the “tracked” headline is one fund's decision, verified twice over, but still one decision. Filing counts are only as good as their collection labels: 26 filings on the current CUSIP, 30 in the issuer-wide scan, and the 4-filing gap is entirely pre-split paper under an old CUSIP. Against that, the insider tape is silent in 90 days and empty in the 1-year window — the double-reported cluster aged out — and the fails lens is absent rather than clean — three “no signal” kinds, not one.

And the price regime is the boundary: every citable window sits after the September 15, 2025 return, so any price-history sentence must start there.

What Would Change the Picture

As-of & Limits

LensAs ofLimit or note
Superinvestors (13F)Jun 30, 202613F figures are as of June 30, 2026, the quarter-end. Funds have up to 45 days after quarter-end to file, so this is the most recent complete picture — and it is always a lagging one. Single current CUSIP 85209E208 for the 13F register (old CUSIP 85209E109 is pre-split). Denominator 147 = funds with usable Q2 data (roster 149); the stock page hero says “held by 1 of 149.” Q1 share counts per holder are not in any workspace file found, so direction labels only are stated; no Q1 share count is backed out. Q3 filings are due by November 16, 2026 and are not in this article. OrbiMed cross-checks: 200,000 × $54.00 = $10,800,000, and the August 14, 2026 13G sums to the same 200,000 shares.
All institutions (13F)Jun 30, 2026By-CUSIP row is the SEC 13F dataset row for SPRB (CUSIP 85209E208); the by-ticker file does not contain SPRB, a coverage fact, not a zero. 63 holders, all 63 long. Shares versus the prior quarter is not in the source row and is not derived from other files. Holders 31 → 63 (+32) and value +130.6% are the stated changes.
Insiders (Form 4)Nov 7, 2026This lens counts only P and S codes. In 90 days: 0 filings, 0 buys, 0 sells — no Form 4 has been filed since July 29, 2026. The 1-year window is now empty: the Parkman double-report (2 buys / 4 sells, October 6, 2025) aged out of the window; one economic buy (256 shares) plus two economic sells (232 and 25 shares) reported twice, not 6 distinct transactions, recorded here as aged-out history. Buy value cited is the aggregate $9,170.33 and sell value $9,840.23; the detail sums are $9,170.32 and $9,840.22, 1-cent rounding differences, not missing transactions. No 1-year transaction price is cited as a market price: the filing prices sit far from the market-price regime on adjacent dates and the cause is undetermined. The site aggregate as of November 7, 2026 has no SPRB entry, consistent with 0 P/S transactions; a writer publishing later must re-check the window.
CongressOct 3, 2026Panel reports data as unavailable in its window; staging holds zero SPRB rows. Re-checked November 7, 2026: still zero SPRB rows in the House staging (October 27 file), the November 7 House PTR refresh (52 new documents), and the Senate file. No congress total is stated; absence of parsed rows is not a verified zero. Any congress claim would need a direct PTR search first.
13D/GAug 14, 2026Collection-scoped phrasing: the headline count (26 filings, 47 reporters, 6,284,213 as-filed row shares) covers current CUSIP 85209E208 only. The issuer-wide parsed-corpus scan (30 filings, 115 rows, 16,879,590 shares, 70 names, 37 CIKs) adds 4 old-CUSIP filings (23 rows, 10,595,377 pre-split shares, including one RiverVest 13D/A carrying the full pre-split total and three 0-share filings). The two CUSIP subsets are never summed. As-filed sums double-count joint reporters and are never presented as shares owned. The 2021–2024 corpus (36 rows, all Spruce Biosciences, Inc.) is a separate collection and is never merged into this series. The old CUSIP is the pre-split common CUSIP, not a different security class.
Short interestOct 15, 2026Shares short and days-to-cover are FINRA twice-monthly settlements; the September 30 and October 15 figures come from FINRA files fetched directly, and the stock-page short panel still shows the September 15 figure. The October 30 settlement file publishes November 10, 2026 (FINRA schedule) and was not available at writing time. Fails-to-deliver are unavailable for SPRB — no fails figure is cited, and absence from the fails list is not a verified zero. Short interest as a share of shares outstanding is not computed: no dated outstanding count for October 15, 2026 exists in this package. The series is reported as settlements, not as a signal.
8-K filingsAug 12, 2026Latest three on the stock-page block, latest first: August 12, 2026 (Items 2.02/9.01), July 27, 2026 (Item 5.02), May 26, 2026 filed for a May 21, 2026 event (Items 5.07/9.01). No 8-K after August 12, 2026 appears in the index. Item 5.02 covers both departures and appointments, which the index does not distinguish. Item labels only; no characterisation of the filings is made here.
PricesNov 6, 2026Price file: daily-refresh cache (fetchedFor November 6, 2026). Closes are the site's daily-refresh cache bars, not dividend-adjusted total return. Only post-September 15, 2025 Nasdaq-return windows are cited; pre-return cache values are quarantined (split-adjusted early values do not sit on the same basis as later actuals, and the discontinuities around the split and the exchange transition are not bridged). History covers 501 trading days from November 7, 2024 to November 6, 2026 only, labeled as all available cache history, with no full-year label. The article's price as-of date is November 6, 2026 — the latest close available at staging; November 7 is a Saturday, so the next close is November 9. The November 6 close ($46.55) was cross-checked against a live Yahoo Finance fetch on November 7, 2026.
FundamentalsFY2025Issuer CIK 1683553. FY revenue, net loss, and total assets from the FY2024 and FY2025 10-Ks (the package's fundamentals series has no SPRB entry); the delisting, split, OTCQB, and relisting dates come from 10-Q notes and proxy filings. Shares outstanding from the 10-Ks (1,372,043 at December 31, 2025; 563,042 at December 31, 2024, split-restated). No current market capitalisation is stated. Going-concern doubt is disclosed in both 10-K risk summaries. Exchange: Nasdaq Capital Market (10-K covers, Section 12(b) registration).

Methodology & disclaimer: 13F holdings are long shares unless stated; reported values include option rows for the all-institutions lens by definition. Short interest is FINRA twice-monthly settlements. Trading costs and taxes are not reflected in any figure. Past patterns are not a promise of future results. For education only — not investment advice.

This article describes filings and market data for education. It is not investment advice. Data: SEC EDGAR 13F (as of June 30, 2026, filed within 45 days), Form 4 detail re-checked through November 7, 2026 (and site aggregate as of November 7, 2026, which has no SPRB entry), Congress panel as of October 3, 2026 (data unavailable for SPRB in the window), SC 13D/G collection through August 14, 2026 (current-CUSIP 85209E208 aggregate; issuer-wide scan noted separately), FINRA short interest at October 15, 2026 settlement (fails-to-deliver unavailable for SPRB). 13F covers long positions of $100M+ managers only and is always a lagging picture. Trading costs and taxes are not reflected.

Related research: Seventeen of 147: Eagle Is 39.8% of the Tracked MercadoLibre Stake — and the Cohort Grew 11.8% While the Price Slipped 1.8% in Q2 · Seven of 147: GQG Is 93.7% of the Tracked Petrobras Stake — and It Added While the Price Fell 22.1% in Q2 · Six of 147: Baker Bros. Holds Nearly Half the Tracked Insmed Stake — and Insiders Sold $42.9M With Zero Buys in 90 Days · Three of 147: Jericho Holds 90.5% of the Tracked Robinhood Stake — and Insiders Sold $133.1M With Zero Buys in 90 Days · Ten of 147: Coatue Is 38.3% of the Tracked Equinix Stake — and Insiders Sold $4.88M With Zero Buys in 90 Days · Two of 147: CenterSquare Holds 96.7% of the Tracked Alexandria Stake — and Insiders Sold $1.36M Against $0.48M of Buys in 90 Days · Three of 147: Deep Track Tripled Its Veradermics Stake — While Insiders Sold $103.1M With Zero Buys in 90 Days · Track the tape on SPRB's stock page and the 13F filing season hub.

Revision history: v1.0 — November 10, 2026. Initial publication. Signals and lens aggregates: sprb_13f_holders_q2.csv. Insider trades: sprb_insider_form4_w90.csv and sprb_insider_form4_w1y.csv. Short-interest series: sprb_short_interest_ftd.csv. 13D/G rows: sprb_scdg_13dg.csv. Exits: sprb_13f_exited_q2.csv.

Related

Three of 147: Deep Track Tripled Its Veradermics Stake — · Methodology: how every number is measured · Practice timing on SPRB

One email a week: the week’s new filings and research. Subscribe free

← Q3 2026 13F early filers: new buys and full exits at 32  ·  13D or 13G? What a 5% Filing Tells You →